Vera Battini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Vera Battini has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Carla Carnovale
Pharmacovigilance and Clinical Research, International Centre for Pesticides and Health Risk Prevention, Department of Biomedical and Clinical Sciences (DIBIC), ASST Fatebenefratelli-Sacco University Hospital, Università Degli Studi Di Milano, Milan, Italy
17 shared publications - Emilio Clementi
University of Milan
11 shared publications - Sonia Radice
Pharmacovigilance & Clinical Research, International Centre for Pesticides and Health Risk Prevention, ASST Fatebenefratelli-Sacco, Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, 20157 Milan, Italy
7 shared publications Giulia Mosini
Pharmacovigilance & Clinical Research, International Centre for Pesticides and Health Risk Prevention, Department of Biomedical and Clinical Sciences (DIBIC), ASST Fatebenefratelli-Sacco University Hospital, Università Degli Studi di Milano, Milan, Italy
6 shared publications- Maurizio Sessa
Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark
6 shared publications - Stefania Cheli
Pharmacovigilance & Clinical Research, International Centre for Pesticides and Health Risk Prevention, ASST Fatebenefratelli-Sacco, Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, 20157 Milan, Italy
6 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1822158
Exploring the impact of GLP-1 analogues and DPP-4 inhibitors on cognitive decline in elderly patients with type 2 diabetes: a competing risks analysis from a real-world cohort
Background: Older adults with type 2 diabetes (T2DM) face an increased risk of cognitive decline. While glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown neuroprotective effects, comparative evidence versus dipeptidyl peptidase-4 inhibitors (DPP-4i) in real-world older populations is limited. Methods: We conducted a retrospective cohort study using health administrative data, including individuals aged ≥65 initiating GLP-1RAs or DPP-4i therapy between 2010 and 2018. Patients with prior cognitive disorders were excluded. The primary outcome was a composite of incident cognitive disorders or death. Analyses were adjusted for clinical and demographic characteristics. Marginal structural models and competing risks methods were used to estimate treatment effects. Both an ‘As treated’ (AT) and an ‘Intention to Treat’ (ITT) designs were employed. Results: A total of 2,579 individuals were included (GLP-1RAs: 393; DPP-4i: 2,186), with a median follow-up of 44 months in the AT analysis. GLP-1RAs users had a lower risk of the composite outcome, especially in the early follow-up (HR at 2 years: 0.5 [95% CI: 0.26–0.93]). Competing-risk analysis showed a lower early risk of death without prior cognitive disorders among GLP-1RA initiators. The point estimate of sub-distribution HR was 0.4 also for cognitive disorders, yet not statistically significant because of the small number of events. Conclusion: GLP-1RAs use was associated with a lower early risk of the composite outcome of cognitive disorders or death compared with DPP-4i in older adults with T2DM. The observed association with cognitive disorders alone was directionally consistent with a potentially lower risk, but the very small number of events precludes firm conclusions regarding a protective effect on cognitive outcomes. Longer follow-up and cognitive-specific evaluations are needed to confirm these associations.
- 15 October 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1822158
Open AccessExploring the impact of GLP-1 analogues and DPP-4 inhibitors on cognitive decline in elderly patients with type 2 diabetes: a competing risks analysis from a real-world cohort
Background: Older adults with type 2 diabetes (T2DM) face an increased risk of cognitive decline. While glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown neuroprotective effects, comparative evidence versus dipeptidyl peptidase-4 inhibitors (DPP-4i) in real-world older populations is limited. Methods: We conducted a retrospective cohort study using health administrative data, including individuals aged ≥65 initiating GLP-1RAs or DPP-4i therapy between 2010 and 2018. Patients with prior cognitive disorders were excluded. The primary outcome was a composite of incident cognitive disorders or death. Analyses were adjusted for clinical and demographic characteristics. Marginal structural models and competing risks methods were used to estimate treatment effects. Both an ‘As treated’ (AT) and an ‘Intention to Treat’ (ITT) designs were employed. Results: A total of 2,579 individuals were included (GLP-1RAs: 393; DPP-4i: 2,186), with a median follow-up of 44 months in the AT analysis. GLP-1RAs users had a lower risk of the composite outcome, especially in the early follow-up (HR at 2 years: 0.5 [95% CI: 0.26–0.93]). Competing-risk analysis showed a lower early risk of death without prior cognitive disorders among GLP-1RA initiators. The point estimate of sub-distribution HR was 0.4 also for cognitive disorders, yet not statistically significant because of the small number of events. Conclusion: GLP-1RAs use was associated with a lower early risk of the composite outcome of cognitive disorders or death compared with DPP-4i in older adults with T2DM. The observed association with cognitive disorders alone was directionally consistent with a potentially lower risk, but the very small number of events precludes firm conclusions regarding a protective effect on cognitive outcomes. Longer follow-up and cognitive-specific evaluations are needed to confirm these associations.
- Open Access
- 3 August 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (8) , 749
Real-World Patterns of Delayed Cutaneous Adverse Reactions to Antimicrobial Therapy in Children: A Case Series and FAERS Analysis Across Age Groups
Background/Objectives: Cutaneous adverse drug reactions (CADRs) account for approximately 45% of all adverse drug reactions. Although most are self-limiting, some may progress to severe cutaneous adverse reactions (SCARs). In children, delayed rashes associated with antimicrobial therapy, particularly beta-lactams, are often misclassified as drug allergies, leading to unnecessary antibiotic avoidance and potentially suboptimal antimicrobial prescribing. This study aimed to characterize delayed antimicrobial-associated CADRs in children and to investigate reporting patterns and factors associated with their clinical management across age groups. Methods: Real-world data from pediatric patients hospitalized in 2023 at the “Ospedale dei Bambini Vittore Buzzi” (Milan, Italy) were integrated with Individual Case Safety Reports from the FDA Adverse Event Reporting System (FAERS). Only cases with documented treatment durations were included. Clinical characteristics, antimicrobial exposure patterns, and factors associated with the reporting of delayed rashes were evaluated. Results: Five pediatric patients developed delayed CADRs after 19–22 days of antimicrobial therapy. Infectious and immunological investigations were negative, and symptoms resolved following drug discontinuation. FAERS analysis identified 97 delayed rash reports, associated with prolonged treatment duration, frequent polytherapy, and higher reporting rates for vancomycin, teicoplanin, and beta-lactam combination regimens. Logistic regression showed that age and polypharmacy were significantly associated with reporting patterns of delayed rash and therapy continuation among reported cases. Conclusions: Among reported cases, delayed antimicrobial-associated CADRs were associated with age and polypharmacy. Improved recognition of these reactions may facilitate appropriate clinical management, support more informed prescribing decisions, and reduce inappropriate antibiotic allergy labeling. Further studies are needed to validate these findings and refine risk-based management strategies in pediatric patients.
- 3 August 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (8) , 749
Open AccessReal-World Patterns of Delayed Cutaneous Adverse Reactions to Antimicrobial Therapy in Children: A Case Series and FAERS Analysis Across Age Groups
Background/Objectives: Cutaneous adverse drug reactions (CADRs) account for approximately 45% of all adverse drug reactions. Although most are self-limiting, some may progress to severe cutaneous adverse reactions (SCARs). In children, delayed rashes associated with antimicrobial therapy, particularly beta-lactams, are often misclassified as drug allergies, leading to unnecessary antibiotic avoidance and potentially suboptimal antimicrobial prescribing. This study aimed to characterize delayed antimicrobial-associated CADRs in children and to investigate reporting patterns and factors associated with their clinical management across age groups. Methods: Real-world data from pediatric patients hospitalized in 2023 at the “Ospedale dei Bambini Vittore Buzzi” (Milan, Italy) were integrated with Individual Case Safety Reports from the FDA Adverse Event Reporting System (FAERS). Only cases with documented treatment durations were included. Clinical characteristics, antimicrobial exposure patterns, and factors associated with the reporting of delayed rashes were evaluated. Results: Five pediatric patients developed delayed CADRs after 19–22 days of antimicrobial therapy. Infectious and immunological investigations were negative, and symptoms resolved following drug discontinuation. FAERS analysis identified 97 delayed rash reports, associated with prolonged treatment duration, frequent polytherapy, and higher reporting rates for vancomycin, teicoplanin, and beta-lactam combination regimens. Logistic regression showed that age and polypharmacy were significantly associated with reporting patterns of delayed rash and therapy continuation among reported cases. Conclusions: Among reported cases, delayed antimicrobial-associated CADRs were associated with age and polypharmacy. Improved recognition of these reactions may facilitate appropriate clinical management, support more informed prescribing decisions, and reduce inappropriate antibiotic allergy labeling. Further studies are needed to validate these findings and refine risk-based management strategies in pediatric patients.
- Open Access
- 15 January 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (1) , 154
Off-Label Ustekinumab and Vedolizumab in Pediatric Anti-TNFα Refractory IBD: Therapeutic Drug Monitoring Insights from a Case Series
Background: Vedolizumab and ustekinumab are increasingly used off-label in pediatric inflammatory bowel disease (IBD) unresponsive or refractory to anti–TNFα therapy. Despite their increasing use in clinical practice, evidence in the pediatric population remains limited, especially regarding therapeutic exposure thresholds and the clinical utility of therapeutic drug monitoring (TDM). Methods: We report a series of five pediatric cases with Crohn’s disease or ulcerative colitis treated with ustekinumab or vedolizumab after anti-TNFα failure. Trough drug concentrations, anti-drug antibodies (ADAs), clinical scores (PCDAI/PUCAI), biomarkers (fecal calprotectin, C-reactive protein), and endoscopic findings were assessed longitudinally. Results: In all cases, we observed recurrent discordance between clinical indices (PCDAI/PUCAI), biochemical markers, and endoscopic activity. Clinical improvement frequently correlated with trough concentrations above commonly cited adult-derived reference ranges (>15 µg/mL for vedolizumab; >3 µg/mL for ustekinumab), although this alignment was not uniform across patients. Notably, one patient developed high-titre ADAs with undetectable ustekinumab levels, yet remained clinically stable, suggesting substantial interindividual variability in pharmacokinetics, immunogenicity, and disease control. Conclusions: Ustekinumab and vedolizumab are promising off-label options for pediatric refractory IBD. In this case series, TDM contributed to the interpretation of pharmacokinetic variability and immunogenicity, offering contextual insights that may support dose adjustments and therapeutic decision-making. Integrating TDM with clinical, biochemical, and endoscopic monitoring may improve optimize individualized treatment in this complex and vulnerable patient group.
- 15 January 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (1) , 154
Open AccessOff-Label Ustekinumab and Vedolizumab in Pediatric Anti-TNFα Refractory IBD: Therapeutic Drug Monitoring Insights from a Case Series
Background: Vedolizumab and ustekinumab are increasingly used off-label in pediatric inflammatory bowel disease (IBD) unresponsive or refractory to anti–TNFα therapy. Despite their increasing use in clinical practice, evidence in the pediatric population remains limited, especially regarding therapeutic exposure thresholds and the clinical utility of therapeutic drug monitoring (TDM). Methods: We report a series of five pediatric cases with Crohn’s disease or ulcerative colitis treated with ustekinumab or vedolizumab after anti-TNFα failure. Trough drug concentrations, anti-drug antibodies (ADAs), clinical scores (PCDAI/PUCAI), biomarkers (fecal calprotectin, C-reactive protein), and endoscopic findings were assessed longitudinally. Results: In all cases, we observed recurrent discordance between clinical indices (PCDAI/PUCAI), biochemical markers, and endoscopic activity. Clinical improvement frequently correlated with trough concentrations above commonly cited adult-derived reference ranges (>15 µg/mL for vedolizumab; >3 µg/mL for ustekinumab), although this alignment was not uniform across patients. Notably, one patient developed high-titre ADAs with undetectable ustekinumab levels, yet remained clinically stable, suggesting substantial interindividual variability in pharmacokinetics, immunogenicity, and disease control. Conclusions: Ustekinumab and vedolizumab are promising off-label options for pediatric refractory IBD. In this case series, TDM contributed to the interpretation of pharmacokinetic variability and immunogenicity, offering contextual insights that may support dose adjustments and therapeutic decision-making. Integrating TDM with clinical, biochemical, and endoscopic monitoring may improve optimize individualized treatment in this complex and vulnerable patient group.
- 6 September 2025
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 39 (4) , 342-347
Olmesartan-Induced Enteropathy: Case Reports and Insights From FDA Adverse Event Reporting System (FAERS)
Olmesartan, an angiotensin II receptor blocker (ARB) approved in 2002, is used to treat hypertension, either alone or with other antihypertensive drugs. It has been frequently associated with sprue-like enteropathy, while few cases of colitis have been reported. Differentiating between sprue-like enteropathy and colitis is of clinical concern, since just the first condition is a well-documented adverse event of olmesartan. Diagnosis of these occurrences is difficult, as symptoms are unspecific namely diarrhoea, weight loss, fatigue, nausea, and abdominal discomfort, with laboratory findings showing anaemia, electrolyte imbalances, and vitamin deficiencies. Here, we report two cases of patients in treatment for hypertension with olmesartan in association with hydrochlorothiazide and amlodipine, who developed sprue-like enteropathy and colitis, respectively. We then conducted a disproportionality analysis of cases retrieved from the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) to assess the association level between these conditions and olmesartan. We found a strong association between olmesartan and sprue-like enteropathy (ROR 8499.53 (95% CI: 8402.05 – 16383.99)). Olmesartan resulted to be associated also with colitis (ROR 2.56 (95% CI: 2.28 – 2.88)). In light of the diagnostic challenges posed by nonspecific symptoms, these findings underscore the importance of distinguishing between the two conditions in patients exposed to olmesartan, to improve the spectrum of knowledge.
- 6 September 2025
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 39 (4) , 342-347
Olmesartan-Induced Enteropathy: Case Reports and Insights From FDA Adverse Event Reporting System (FAERS)
Olmesartan, an angiotensin II receptor blocker (ARB) approved in 2002, is used to treat hypertension, either alone or with other antihypertensive drugs. It has been frequently associated with sprue-like enteropathy, while few cases of colitis have been reported. Differentiating between sprue-like enteropathy and colitis is of clinical concern, since just the first condition is a well-documented adverse event of olmesartan. Diagnosis of these occurrences is difficult, as symptoms are unspecific namely diarrhoea, weight loss, fatigue, nausea, and abdominal discomfort, with laboratory findings showing anaemia, electrolyte imbalances, and vitamin deficiencies. Here, we report two cases of patients in treatment for hypertension with olmesartan in association with hydrochlorothiazide and amlodipine, who developed sprue-like enteropathy and colitis, respectively. We then conducted a disproportionality analysis of cases retrieved from the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) to assess the association level between these conditions and olmesartan. We found a strong association between olmesartan and sprue-like enteropathy (ROR 8499.53 (95% CI: 8402.05 – 16383.99)). Olmesartan resulted to be associated also with colitis (ROR 2.56 (95% CI: 2.28 – 2.88)). In light of the diagnostic challenges posed by nonspecific symptoms, these findings underscore the importance of distinguishing between the two conditions in patients exposed to olmesartan, to improve the spectrum of knowledge.
- Open Access
- 19 April 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (8) , 3881
NAT2 Acetylation Status Predicts Hepatotoxicity During Antituberculosis Therapy: Cumulative Risk Analysis of a Multiethnic Cohort
Antituberculosis drug-induced hepatotoxicity (ATDH) is a common adverse drug reaction often requiring treatment interruption, complicating tuberculosis management. The slow acetylator phenotype, characterized by reduced N-acetyltransferase 2 (NAT2) enzyme activity, is associated with increased hepatotoxicity risk, while rapid acetylators are associated with a higher risk of therapeutic failure. This study investigates the association between the NAT2 acetylation phenotype and ATDH occurrence, with an emphasis on its predictive value in regard to a multiethnic population and its impact on the timing of ATDH onset. A retrospective observational study was conducted on tuberculosis patients treated at Luigi Sacco Hospital, Milan, Italy (July 2020–September 2023). The NAT2 genotyping identified slow and rapid/intermediate acetylators. Cumulative incidence analysis and Fine–Gray competing risks regression models were used to assess ATDH risk and onset timing. Among 102 patients, 21.6% developed ATDH, including 16.7% with slow and 4.9% with rapid/intermediate acetylators. ATDH onset was significantly earlier in regard to slow acetylators (median 0.5 vs. 2 months, interquartile range-IQR: 0.5–3 vs. 1.7–5.5). Slow acetylators were associated with a higher risk of developing ATDH (Sub-distribution hazard ratio, SHR = 3.05; 95% confidence interval-CI: 1.17–7.95; p = 0.02), even after adjusting for confounders. The NAT2 acetylation phenotype strongly influences ATDH risk and timing. Early acetylator status identification may enable dose adjustments, enhancing treatment safety. These findings highlight the role of pharmacogenetics in optimizing antituberculosis therapy by improving efficacy and minimizing toxicity.
- 19 April 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (8) , 3881
Open AccessNAT2 Acetylation Status Predicts Hepatotoxicity During Antituberculosis Therapy: Cumulative Risk Analysis of a Multiethnic Cohort
Antituberculosis drug-induced hepatotoxicity (ATDH) is a common adverse drug reaction often requiring treatment interruption, complicating tuberculosis management. The slow acetylator phenotype, characterized by reduced N-acetyltransferase 2 (NAT2) enzyme activity, is associated with increased hepatotoxicity risk, while rapid acetylators are associated with a higher risk of therapeutic failure. This study investigates the association between the NAT2 acetylation phenotype and ATDH occurrence, with an emphasis on its predictive value in regard to a multiethnic population and its impact on the timing of ATDH onset. A retrospective observational study was conducted on tuberculosis patients treated at Luigi Sacco Hospital, Milan, Italy (July 2020–September 2023). The NAT2 genotyping identified slow and rapid/intermediate acetylators. Cumulative incidence analysis and Fine–Gray competing risks regression models were used to assess ATDH risk and onset timing. Among 102 patients, 21.6% developed ATDH, including 16.7% with slow and 4.9% with rapid/intermediate acetylators. ATDH onset was significantly earlier in regard to slow acetylators (median 0.5 vs. 2 months, interquartile range-IQR: 0.5–3 vs. 1.7–5.5). Slow acetylators were associated with a higher risk of developing ATDH (Sub-distribution hazard ratio, SHR = 3.05; 95% confidence interval-CI: 1.17–7.95; p = 0.02), even after adjusting for confounders. The NAT2 acetylation phenotype strongly influences ATDH risk and timing. Early acetylator status identification may enable dose adjustments, enhancing treatment safety. These findings highlight the role of pharmacogenetics in optimizing antituberculosis therapy by improving efficacy and minimizing toxicity.
- Open Access
- 7 February 2025
- Published by Springer Nature in Drug Safety
- Vol. 48 (5) , 513-526
Network Analysis and Machine Learning for Signal Detection and Prioritization Using Electronic Healthcare Records and Administrative Databases: A Proof of Concept in Drug-Induced Acute Myocardial Infarction
Background Safety signals for potential drug-induced adverse events (AEs) typically emerge from multiple data sources, primarily spontaneous reporting systems, despite known limitations. Increasingly, real-world data from sources such as electronic health records (EHRs) and administrative databases are leveraged for signal detection. Although network analysis has shown promise in mapping relationships between clinical attributes for signal detection in spontaneous reporting system databases, its application in real-world data from EHRs and administrative databases remains limited. Objective This study aimed to evaluate the performance of network analysis in detecting safety signals within Italian administrative databases, using drug-induced acute myocardial infarction (AMI) as a proof of concept. Methods We employed a case–crossover design to explore the association between drug exposure and AMI using the Healthcare Administrative Database of Mantova, Italy, from 2014 to 2018. Patients with their first AMI hospitalization were identified after a 365-day washout period to exclude prior hospitalizations. We constructed a network to analyse the relationships between prescribed drugs and diagnoses, represented as nodes, with undirected edges illustrating their interactions. For each patient with AMI, we identified all diagnoses and drugs recorded or redeemed within 365 days of the first AMI episode and generated various drug–diagnosis, drug–drug, and diagnosis–diagnosis pairs. We calculated the frequency of these pairs, and three types of edge weights quantified the strength of connections. We identified outlier drug–AMI pairs using a predictive score (F) based on frequency (C) and full edge weights (WF), with validation for known AMI associations. We prioritized signals using the F score, C of AMI, and WF, analysed through k-means clustering to identify patterns in the data. Results From 2014 to 2018, a total of 3918 patients had an AMI, with 4686 AMI diagnoses. Of those, 2866 had prescriptions in the previous year, totalling 498,591 prescriptions. A network analysis identified 2968 unique nodes, revealing 529,935 diagnosis–diagnosis connections, 235,380 drug–diagnosis connections, and 102,831 drug–drug connections. The median number of connections (C) was 404 (Q1–Q3: 194–671) for drug nodes and 380 (Q1–Q3: 216–664) for diagnosis nodes. The median WF was 11.8 (Q1–Q3: 9–14), and the median F score across pairs was 0.1 (Q1–Q3: 0.1–0.3). A total of 249 potential safety signals were detected, with 63.4% aligning with known AEs. Among the remaining signals, 80 were prioritized, and five emerged as the highest priority: terazosin, tamsulosin, allopurinol, esomeprazole, and omeprazole. Conclusions Overall, our novel method demonstrates that network analysis is a valuable tool for signal detection and prioritization in drug-induced AEs based on EHRs and administrative databases.
- 7 February 2025
- Published by Springer Nature in Drug Safety
- Vol. 48 (5) , 513-526
Open AccessNetwork Analysis and Machine Learning for Signal Detection and Prioritization Using Electronic Healthcare Records and Administrative Databases: A Proof of Concept in Drug-Induced Acute Myocardial Infarction
Background Safety signals for potential drug-induced adverse events (AEs) typically emerge from multiple data sources, primarily spontaneous reporting systems, despite known limitations. Increasingly, real-world data from sources such as electronic health records (EHRs) and administrative databases are leveraged for signal detection. Although network analysis has shown promise in mapping relationships between clinical attributes for signal detection in spontaneous reporting system databases, its application in real-world data from EHRs and administrative databases remains limited. Objective This study aimed to evaluate the performance of network analysis in detecting safety signals within Italian administrative databases, using drug-induced acute myocardial infarction (AMI) as a proof of concept. Methods We employed a case–crossover design to explore the association between drug exposure and AMI using the Healthcare Administrative Database of Mantova, Italy, from 2014 to 2018. Patients with their first AMI hospitalization were identified after a 365-day washout period to exclude prior hospitalizations. We constructed a network to analyse the relationships between prescribed drugs and diagnoses, represented as nodes, with undirected edges illustrating their interactions. For each patient with AMI, we identified all diagnoses and drugs recorded or redeemed within 365 days of the first AMI episode and generated various drug–diagnosis, drug–drug, and diagnosis–diagnosis pairs. We calculated the frequency of these pairs, and three types of edge weights quantified the strength of connections. We identified outlier drug–AMI pairs using a predictive score (F) based on frequency (C) and full edge weights (WF), with validation for known AMI associations. We prioritized signals using the F score, C of AMI, and WF, analysed through k-means clustering to identify patterns in the data. Results From 2014 to 2018, a total of 3918 patients had an AMI, with 4686 AMI diagnoses. Of those, 2866 had prescriptions in the previous year, totalling 498,591 prescriptions. A network analysis identified 2968 unique nodes, revealing 529,935 diagnosis–diagnosis connections, 235,380 drug–diagnosis connections, and 102,831 drug–drug connections. The median number of connections (C) was 404 (Q1–Q3: 194–671) for drug nodes and 380 (Q1–Q3: 216–664) for diagnosis nodes. The median WF was 11.8 (Q1–Q3: 9–14), and the median F score across pairs was 0.1 (Q1–Q3: 0.1–0.3). A total of 249 potential safety signals were detected, with 63.4% aligning with known AEs. Among the remaining signals, 80 were prioritized, and five emerged as the highest priority: terazosin, tamsulosin, allopurinol, esomeprazole, and omeprazole. Conclusions Overall, our novel method demonstrates that network analysis is a valuable tool for signal detection and prioritization in drug-induced AEs based on EHRs and administrative databases.
- 27 December 2024
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
NAT2 Slow Acetylator Phenotype as a Significant Risk Factor for Hepatotoxicity Caused by Antituberculosis Drugs: Results From a Multiethnic Nested Case-Control Study
Background: Under standard therapies, the incidence of drug-induced liver injury (DILI) in patients with tuberculosis ranges from 2% to 28%. Numerous studies have identified the risk factors for antituberculosis DILI; however, none have been conducted in a multiethnic real-world setting. The primary outcome of the current study was to identify the risk factors that could be used as the best predictors of DILI in a multiethnic cohort. Methods: A nested case-control study was conducted in patients at the tuberculosis clinic of Luigi Sacco Hospital in Milan. Results: The study included 102 patients (mean age [SD], 45.6 [15.6] years). For each patient with hepatotoxicity, 2 controls were matched for sex, age, body mass index, tuberculosis/tuberculosis infection diagnosis, and index date. We found that N-acetyltransferase 2 gene (NAT2) slow acetylator status was the best independent predictor of DILI (odds ratio, 5.97 [95% confidence interval, 1.38–25.76]; P = .02]. Conclusions: NAT2 genotype–guided dosing may help optimize antituberculosis drug treatment and prevent treatment failure. Clinical Trials Registration: ClinicalTrials.gov NCT06539455
- 27 December 2024
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
NAT2 Slow Acetylator Phenotype as a Significant Risk Factor for Hepatotoxicity Caused by Antituberculosis Drugs: Results From a Multiethnic Nested Case-Control Study
Background: Under standard therapies, the incidence of drug-induced liver injury (DILI) in patients with tuberculosis ranges from 2% to 28%. Numerous studies have identified the risk factors for antituberculosis DILI; however, none have been conducted in a multiethnic real-world setting. The primary outcome of the current study was to identify the risk factors that could be used as the best predictors of DILI in a multiethnic cohort. Methods: A nested case-control study was conducted in patients at the tuberculosis clinic of Luigi Sacco Hospital in Milan. Results: The study included 102 patients (mean age [SD], 45.6 [15.6] years). For each patient with hepatotoxicity, 2 controls were matched for sex, age, body mass index, tuberculosis/tuberculosis infection diagnosis, and index date. We found that N-acetyltransferase 2 gene (NAT2) slow acetylator status was the best independent predictor of DILI (odds ratio, 5.97 [95% confidence interval, 1.38–25.76]; P = .02]. Conclusions: NAT2 genotype–guided dosing may help optimize antituberculosis drug treatment and prevent treatment failure. Clinical Trials Registration: ClinicalTrials.gov NCT06539455
- Open Access
New data-driven method to predict the therapeutic indication of redeemed prescriptions in secondary data sources: a case study on antiseizure medications users aged ≥65 identified in Danish registries
Objectives We aimed to develop a new data-driven method to predict the therapeutic indication of redeemed prescriptions in secondary data sources using antiepileptic drugs among individuals aged ≥65 identified in Danish registries. Design This was an incident new-user register-based cohort study using Danish registers. Setting The study setting was Denmark and the study period was 2005–2017. Participants Participants included antiepileptic drug users in Denmark aged ≥65 with a confirmed diagnosis of epilepsy. Primary and secondary outcome measures Sensitivity served as the performance measure of the algorithm. Results The study population comprised 8609 incident new users of antiepileptic drugs. The sensitivity of the algorithm in correctly predicting the therapeutic indication of antiepileptic drugs in the study population was 65.3% (95% CI 64.4 to 66.2). Conclusions The algorithm demonstrated promising properties in terms of overall sensitivity for predicting the therapeutic indication of redeemed antiepileptic drugs by older individuals with epilepsy, correctly identifying the therapeutic indication for 6 out of 10 individuals using antiepileptic drugs for epilepsy.
Open AccessNew data-driven method to predict the therapeutic indication of redeemed prescriptions in secondary data sources: a case study on antiseizure medications users aged ≥65 identified in Danish registries
Objectives We aimed to develop a new data-driven method to predict the therapeutic indication of redeemed prescriptions in secondary data sources using antiepileptic drugs among individuals aged ≥65 identified in Danish registries. Design This was an incident new-user register-based cohort study using Danish registers. Setting The study setting was Denmark and the study period was 2005–2017. Participants Participants included antiepileptic drug users in Denmark aged ≥65 with a confirmed diagnosis of epilepsy. Primary and secondary outcome measures Sensitivity served as the performance measure of the algorithm. Results The study population comprised 8609 incident new users of antiepileptic drugs. The sensitivity of the algorithm in correctly predicting the therapeutic indication of antiepileptic drugs in the study population was 65.3% (95% CI 64.4 to 66.2). Conclusions The algorithm demonstrated promising properties in terms of overall sensitivity for predicting the therapeutic indication of redeemed antiepileptic drugs by older individuals with epilepsy, correctly identifying the therapeutic indication for 6 out of 10 individuals using antiepileptic drugs for epilepsy.
- Open Access
- 30 April 2024
- Published by Springer Nature in Drug Safety
- Vol. 47 (9) , 895-907
Timing Matters: A Machine Learning Method for the Prioritization of Drug–Drug Interactions Through Signal Detection in the FDA Adverse Event Reporting System and Their Relationship with Time of Co-exposure
Introduction Current drug–drug interaction (DDI) detection methods often miss the aspect of temporal plausibility, leading to false-positive disproportionality signals in spontaneous reporting system (SRS) databases. Objective This study aims to develop a method for detecting and prioritizing temporally plausible disproportionality signals of DDIs in SRS databases by incorporating co-exposure time in disproportionality analysis. Methods The method was tested in the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS). The CRESCENDDI dataset of positive controls served as the primary source of true-positive DDIs. Disproportionality analysis was performed considering the time of co-exposure. Temporal plausibility was assessed using the flex point of cumulative reporting of disproportionality signals. Potential confounders were identified using a machine learning method (i.e. Lasso regression). Results Disproportionality analysis was conducted on 122 triplets with more than three cases, resulting in the prioritization of 61 disproportionality signals (50.0%) involving 13 adverse events, with 61.5% of these included in the European Medicine Agency’s (EMA’s) Important Medical Event (IME) list. A total of 27 signals (44.3%) had at least ten cases reporting the triplet of interest, and most of them (n = 19; 70.4%) were temporally plausible. The retrieved confounders were mainly other concomitant drugs. Conclusions Our method was able to prioritize disproportionality signals with temporal plausibility. This finding suggests a potential for our method in pinpointing signals that are more likely to be furtherly validated.
- 30 April 2024
- Published by Springer Nature in Drug Safety
- Vol. 47 (9) , 895-907
Open AccessTiming Matters: A Machine Learning Method for the Prioritization of Drug–Drug Interactions Through Signal Detection in the FDA Adverse Event Reporting System and Their Relationship with Time of Co-exposure
Introduction Current drug–drug interaction (DDI) detection methods often miss the aspect of temporal plausibility, leading to false-positive disproportionality signals in spontaneous reporting system (SRS) databases. Objective This study aims to develop a method for detecting and prioritizing temporally plausible disproportionality signals of DDIs in SRS databases by incorporating co-exposure time in disproportionality analysis. Methods The method was tested in the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS). The CRESCENDDI dataset of positive controls served as the primary source of true-positive DDIs. Disproportionality analysis was performed considering the time of co-exposure. Temporal plausibility was assessed using the flex point of cumulative reporting of disproportionality signals. Potential confounders were identified using a machine learning method (i.e. Lasso regression). Results Disproportionality analysis was conducted on 122 triplets with more than three cases, resulting in the prioritization of 61 disproportionality signals (50.0%) involving 13 adverse events, with 61.5% of these included in the European Medicine Agency’s (EMA’s) Important Medical Event (IME) list. A total of 27 signals (44.3%) had at least ten cases reporting the triplet of interest, and most of them (n = 19; 70.4%) were temporally plausible. The retrieved confounders were mainly other concomitant drugs. Conclusions Our method was able to prioritize disproportionality signals with temporal plausibility. This finding suggests a potential for our method in pinpointing signals that are more likely to be furtherly validated.
- 18 April 2024
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 17 (5-6) , 441-453
Exploring the impact of co-exposure timing on drug-drug interactions in signal detection through spontaneous reporting system databases: a scoping review
Drug-drug interactions (DDIs) are defined as the pharmacological effects produced by the concomitant administration of two or more drugs. To minimize false positive signals and ensure their validity when analyzing Spontaneous Reporting System (SRS) databases, it has been suggested to incorporate key pharmacological principles, such as temporal plausibility. the scoping review of the literature was completed using MEDLINE from inception to March 2023. Included studies had to provide detailed methods for identifying DDIs in SRS databases. Any methodological approach and adverse event were accepted. Descriptive analyzes were excluded as we focused on automatic signal detection methods. The result is an overview of all the available methods for DDI signal detection in SRS databases, with a specific focus on the evaluation of the co-exposure time of the interacting drugs. It is worth noting that only a limited number of studies (n = 3) have attempted to address the issue of overlapping drug administration times. Current guidelines for signal validation focus on factors like the number of reports and temporal association, but they lack guidance on addressing overlapping drug administration times, highlighting a need for further research and method development.
- 18 April 2024
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 17 (5-6) , 441-453
Exploring the impact of co-exposure timing on drug-drug interactions in signal detection through spontaneous reporting system databases: a scoping review
Drug-drug interactions (DDIs) are defined as the pharmacological effects produced by the concomitant administration of two or more drugs. To minimize false positive signals and ensure their validity when analyzing Spontaneous Reporting System (SRS) databases, it has been suggested to incorporate key pharmacological principles, such as temporal plausibility. the scoping review of the literature was completed using MEDLINE from inception to March 2023. Included studies had to provide detailed methods for identifying DDIs in SRS databases. Any methodological approach and adverse event were accepted. Descriptive analyzes were excluded as we focused on automatic signal detection methods. The result is an overview of all the available methods for DDI signal detection in SRS databases, with a specific focus on the evaluation of the co-exposure time of the interacting drugs. It is worth noting that only a limited number of studies (n = 3) have attempted to address the issue of overlapping drug administration times. Current guidelines for signal validation focus on factors like the number of reports and temporal association, but they lack guidance on addressing overlapping drug administration times, highlighting a need for further research and method development.